Showing 1 - 9 of 9
Novo Nordisk Completes Landmark Diabetes Affordability Project
Published on 31/07/2025
» Bangkok, - Novo Nordisk Pharma (Thailand) Ltd. (Novo Nordisk) today announced the successful completion of the Affordability Project in Thailand as part of its ongoing commitment to drive change in diabetes in the country. This transformative initiative was launched in collaboration with the Department of Medical Services, Ministry of Public Health. Over the past three years, the project has actively addressed the rising diabetic problems in Thailand through a public-private partnership with the Thai state-owned Rajavithi Hospital, Institute of Medical Research & Technology Assessment and Bureau of Medical System Supervision as the project’s main implementor.
Novo Nordisk, Nanyang Launch Shoes for Haemophilia Awareness
Published on 08/05/2025
» Bangkok, Thailand – 6 May 2025 – Novo Nordisk Pharma (Thailand) Ltd. (Novo Nordisk), a global healthcare company committed to driving change in chronic diseases, has announced the delivery of unique shoes, produced in collaboration with renowned Thai shoe manufacturer Nanyang, to the Thai Haemophilia Patient Club. The collaboration aims to enhance awareness of haemophilia in Thailand, underscoring the message of equitable access to healthcare.
Novo Nordisk Launches Blockchain to Fight Counterfeit Drugs
Published on 27/03/2025
» Novo Nordisk Thailand has announced the successful implementation of a blockchain-based traceability solution to verify the authenticity of Ozempic® across the supply chain, addressing the growing threat of counterfeit medicines and enhancing patient safety.
Novo Nordisk and Bangkok Unite for a Healthier Future
Published on 17/03/2025
» To mark World Obesity Day 2025, Novo Nordisk participated in the Chula Obesity Day event, organised by Chulalongkorn University. As part of the session “How Cities and Partnerships Drive a Sustainable Future Against Obesity,” which aligned with the global theme “Changing Systems, Healthier Lives,” Thai authorities—including the Thai Health Promotion Foundation and the Bangkok Metropolitan Administration (BMA)—gathered to discuss the growing obesity crisis in Thailand and the role of public-private partnerships in addressing it.
Novo Nordisk and Diabetes Association Inspire Diabetics at Bangkok Ride & Run 2024
Published on 20/12/2024
» Diabetes is a global health issue that continues to rise, including in Thailand. In 2021, 537 million people worldwide were affected by diabetes, and this number is expected to increase to 643 million by 2030. Diabetes causes 6.7 million deaths annually, approximately one death every 5 seconds. The International Diabetes Federation (IDF) also forecasts that in 2040, Thailand may have up to 5.3 million people living with diabetes. This disease is also a significant cause of other non-communicable diseases such as heart disease, stroke, hypertension, and chronic kidney disease, etc.
Affordability Project: Revolutionizing Diabetes Care and Creating Equal Access
Published on 06/11/2024
» The global diabetes crisis is worsening. With over 537 million people currently living with diabetes worldwide, the International Diabetes Federation (IDF) predicts this number to soar to 643 million by 2030. Diabetes is a leading cause of death, claiming 6.7 million lives each year, or one death every 5 seconds. Thailand is no exception, with an estimated 5.3 million people expected to be living with diabetes by 2040. Alarmingly, nearly half of these cases remain undiagnosed. Diabetes not only poses serious health risks, including heart disease and kidney disease, but also imposes a significant economic burden, costing the country 47.596 billion baht annually.
Siriraj Hospital Partners with Novo Nordisk for Chronic Disease Research
Published on 28/08/2024
» Novo Nordisk Pharma (Thailand) Ltd. has signed a Memorandum of Understanding (MOU) with the Faculty of Medicine Siriraj Hospital, Mahidol University. The aim is to promote collaboration in the study and research of medications for diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. This collaboration will also provide opportunities for patients to participate in clinical research and offers researchers more options in clinical studies. Additionally, this partnership also aims to facilitate training, joint research projects, and the exchange of innovative information and knowledge.
Novo Nordisk (Thailand) Announces Equality Policy to Meet Pride month to support LGBTQ employees
Published on 25/07/2022
» Novo Nordisk Thailand, a leading innovative pharmaceutical company for over 39 years in Thailand, as announced the welfare policy to support participation and equality (Diversity & Inclusion ) for LGBTQ employees whether they are lesbian, gay, bisexual, queer, etc. This policy represents non-discrimination against LGBTQ colleague or future employees. . The company has increased welfare coverage for LGBTQ employees who can take marital leave and receive marriage financial support. Employees also take leave to support a new child into their family. The company expects these benefits to be a real wish to help drive diversity & inclusion in Thai organizations and society.
“Novo Nordisk Thailand” buys renewable energy from EGAT
Published on 06/07/2021
» Novo Nordisk Thailand has purchased renewable energy production credits from Electricity Generating Authority of Thailand (EGAT) to advance its global zero environmental impact policy.